Hickie, I B, Wilson, A J, Wright, J M et al. · The Journal of clinical psychiatry · 2000 · DOI
This study tested whether a medication called moclobemide could help people with ME/CFS. Ninety patients received either moclobemide or a placebo for several weeks. About half of those taking moclobemide felt better, compared to one-third taking placebo—mainly reporting more energy and vigor rather than improvement in mood. The medication appeared to work best for people who also had immune system problems.
This study addresses a critical unmet need by providing evidence that a pharmacological intervention can improve core ME/CFS symptoms—particularly energy and vigor—rather than only addressing comorbid depression. The finding that moclobemide's benefit is independent of mood changes suggests a direct effect on fatigue mechanisms rather than a secondary consequence of mood improvement, which could inform future mechanistic research and treatment approaches.
This study does not establish that moclobemide is a cure or that it works for all ME/CFS patients. The confidence interval crosses 1.0 (0.9–5.1), meaning the difference between moclobemide and placebo, while suggestive, is not statistically definitive. It also does not explain why moclobemide works or identify which specific patients are most likely to benefit.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →